Cytokinetics (CYTK) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cytokinetics Reports Third Quarter 2024 Financial Results
November 6, 2024 4:00 PM ESTRolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3
COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil,
and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4
Plan to Advance CK-089, Fast Skeletal Muscle Troponin Activator,
into First-In-Human Study in Q4 2024
~$1.3 Billion in Cash, Cash Equivalents and Investments as of September 30, 2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a... More
